Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of MDR-001 with Rifampin and Itraconazole in Healthy Adults
NCT07550621Phase 1Not yet recruiting
- Sponsor
- MindRank
- Start
- May 2026
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of MDR-001 in obesity (2 arms), sponsored by MindRank. Primary endpoints: Maximum Observed Plasma Concentration, Area Under the Plasma Concentration-Time Curve From Time Zero to Last Quantifiable Concentration and 1 more. Planned start May 2026; status: not yet recruiting.
02
Drugs
MDR-001
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07550621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07550621.